Molecular investigation of carbapenem resistance among multidrug-resistant Pseudomonas aeruginosa isolated clinically in Thailand

Microbiology and Immunology

Volumn 57, Issue 3, 2013, Pages 170-178

  Khuntayaporn, Piyatip ^a   Montakantikul, Preecha ^a   Santanirand, Pitak ^b   Kiratisin, Pattarachai ^c   Chomnawang, Mullika Traidej ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

lactamases; Carbapenem resistance mechanisms; Efflux pump systems; Multidrug resistant Pseudomonas aeruginosa

Indexed keywords

BETA LACTAMASE AMPC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORINASE; CIPROFLOXACIN; DORIPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; MESSENGER RNA; PIPERACILLIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; IMP 1 GENE; IMP 14 GENE; MEXAB GENE; MEXCD GENE; MEXXY GENE; MULTIDRUG RESISTANCE; NONHUMAN; OPRD GENE; OPRJ GENE; OPRM GENE; PSEUDOMONAS AERUGINOSA; THAILAND; UPREGULATION; VIM 2 GENE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION PROFILING; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TERTIARY CARE CENTERS; THAILAND;

EID: 84875243491     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12021     Document Type: Article

References (47)

1. Zhanel G.G., Wiebe R., Dilay L., Thomson K., Rubinstein E., Hoban D.J., Noreddin A.M., Karlowsky J.A. (2007) Comparative review of the carbapenems. Drugs 67(7): 1027-52.
2. Walsh T.R. (2008) Clinically significant carbapenemases: an update. Curr Opin Infect Dis 21(4): 367-71.
3. Masterton R.G. (2009) The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents 33(2): 105-110.
4. Tenover F.C. (2006) Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control 34 (5 Suppl. 1): S3-10; discussion S64-73.
5. Poole K. (2002) Mechanisms of bacterial biocide and antibiotic resistance. Symp Ser Soc Appl Microbiol 31: 55S-64S.
6. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1): 1-12.
7. Kiska D.L., Gilligan P.H. (2003) Pseudomonas. In: Murray P.R., Baron E.J., Jorgensen J.H., Pfealler M.A., Yolken R.H., eds. Manual of Clinical Microbiology, 8th edn. Washington, DC: ASM Press, pp. 719-28.
8. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50(1): 43-8.
9. Rosenthal V.D., Maki D.G., Jamulitrat S., Medeiros E.A., Todi S.K., Gomez D.Y., Leblebicioglu H., Abu Khader I., Miranda Novales M.G., Berba R., Ramirez F.M., Wong A., Barkat O.R., Pino L., Duenas Z., Mitrev H., Bijie V., Gurskis S.S., Kanj T., Mapp R.F., Hidalgo N., Ben Jaballah L., Raka A., Gikas A., Ahmed Thu le T.A., Guzman Siritt M.E. (2010) International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 38(2): 95-104 e2.
10. European Centre for Disease Prevention and Control. (2010) Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, pp. 57-70.
11. Mesaros N., Nordmann P., Plesiat P., Roussel-Delvallez M., Van Eldere J., Glupczynski Y., Van Laethem Y., Jacobs F., Lebecque P., Malfroot A., Tulkens P.M., Van Bambeke F. (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13(6): 560-78.
12. Livermore D.M. (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34(5): 634-40.
13. Kumar A., Schweizer H.P. (2005) Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 57(10): 1486-513.
14. Masuda N., Sakagawa E., Ohya S. (1995) Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 39(3): 645-9.
15. Jacoby G.A. (2009) AmpC beta-lactamases. Clin Microbiol Rev 22(1): 161-82.
16. Sacha P., Wieczorek P., Hauschild T., Zorawski M., Olszanska D., Tryniszewska E. (2008) Metallo-beta-lactamases of Pseudomonas aeruginosa-a novel mechanism resistance to beta-lactam antibiotics. Folia Histochem Cytobiol 46(2): 137-42.
17. Trias J., Nikaido H. (1990) Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. J Biol Chem 265(26): 15680-4.
18. Gutierrez O., Juan C., Cercenado E., Navarro F., Bouza E., Coll P., Perez J.L., Oliver A. (2007) Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother 51(12): 4329-35.
19. Wolter D.J., Hanson N.D., Lister P.D. (2004) Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol Lett 236(1): 137-43.
20. Queenan A.M., Bush K. (2007) Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20(3): 440-58.
21. Walsh T.R., Toleman M.A., Poirel L., Nordmann P. (2005) Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 18(2): 306-25.
22. Strateva T., Yordanov D. (2009) Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J Med Microbiol 58(Pt 9): 1133-48.
23. Okamoto K., Gotoh N., Nishino T. (2001) Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob Agents Chemother 45(7): 1964-71.
24. Wang J., Zhou J.Y., Qu T.T., Shen P., Wei Z.Q., Yu Y.S., Li L.J. (2010) Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int J Antimicrob Agents 35(5): 486-91.
25. Rodriguez-Martinez J.M., Poirel L., Nordmann P. (2009) Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53(11): 4783-8.
26. Clinical and Laboratory Standards Institute. (2011) Performance standards for antimicrobial susceptibility testing. Wayne, PA, USA: Clinical and Laboratory Standards Institute.
27. Falagas M.E., Koletsi P.K., Bliziotis I.A. (2006) The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 55(Pt 12): 1619-29.
28. Khuntayaporn P., Montakantikul P., Mootsikapun P., Thamlikitkul V., Chomnawang M.T. (2012) Prevalence and genotypic relatedness of carbapenem resistance among multidrug-resistant P. aeruginosa in tertiary hospitals across Thailand. Ann Clin Microbiol Antimicrob 11: 25.
29. Winsor G.L., Lam D.K., Fleming L., Lo R., Whiteside M.D., Yu N.Y., Hancock R.E., Brinkman F.S. (2011) Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes. Nucleic Acids Res 39 (Database issue): D596-600.
30. Dumas J.L., van Delden C., Perron K., Kohler T. (2006) Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol Lett 254(2): 217-25.
31. Cabot G., Ocampo-Sosa A.A., Tubau F., Macia M.D., Rodriguez C., Moya B., Zamorano L., Suarez C., Pena C., Martinez-Martinez L., Oliver A. (2011) Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55(5): 1906-11.
32. De Champs C., Poirel L., Bonnet R., Sirot D., Chanal C., Sirot J., Nordmann P. (2002) Prospective survey of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 46(9): 3031-4.
33. Qu T.T., Zhang J.L., Wang J., Tao J., Yu Y.S., Chen Y.G., Zhou J.Y., Li L.J. (2009) Evaluation of phenotypic tests for detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa strains in China. J Clin Microbiol 47(4): 1136-42.
34. Poirel L., Walsh T.R., Cuvillier V., Nordmann P. (2011) Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70(1): 119-23.
35. Okamoto K., Gotoh N., Nishino T. (2002) Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J Infect Chemother 8(4): 371-3.
36. Masuda N., Sakagawa E., Ohya S., Gotoh N., Nishino T. (2001) Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to beta-lactams due to reduced expression of the ampC beta-lactamase. Antimicrob Agents Chemother 45(4): 1284-6.
37. Wolter D.J., Hanson N.D., Lister P.D. (2005) AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump. Antimicrob Agents Chemother 49(11): 4763-6.
38. El Amin N., Giske C.G., Jalal S., Keijser B., Kronvall G., Wretlind B. (2005) Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113(3): 187-96.
39. Lister P.D., Wolter D.J., Hanson N.D. (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22(4): 582-610.
40. Hocquet D., Muller A., Blanc K., Plesiat P., Talon D., Monnet D.L., Bertrand X. (2008) Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 52(3): 1173-5.
41. Aires J.R., Kohler T., Nikaido H., Plesiat P. (1999) Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 43(11): 2624-8.
42. Mine T., Morita Y., Kataoka A., Mizushima T., Tsuchiya T. (1999) Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother 43(2): 415-7.
43. Manoharan A., Chatterjee S., Mathai D. (2010) Detection and characterization of metallo beta lactamases producing Pseudomonas aeruginosa. Indian J Med Microbiol 28(3): 241-4.
44. Hirakata Y., Yamaguchi T., Nakano M., Izumikawa K., Mine M., Aoki S., Kondoh A., Matsuda J., Hirayama M., Yanagihara K., Miyazaki Y., Tomono K., Yamada Y., Kamihira S., Kohno S. (2003) Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis 37(1): 26-32.
45. Zavascki A.P., Barth A.L., Goncalves A.L., Moro A.L., Fernandes J.F., Martins A.F., Ramos F., Goldani L.Z. (2006) The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother 58(2): 387-92.
46. Tam V.H., Chang K.T., Schilling A.N., LaRocco M.T., Genty L.O., Garey K.W. (2009) Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis 63(3): 279-85.
47. Rodriguez-Martinez J.M., Poirel L., Nordmann P. (2009) Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53(5): 1766-71.